Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

The U.S. Food and Drug Administration (FDA) recently approved the use of Darzalex Faspro (daratumumab and hyaluronidase-fihj) ...

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

Caring for someone with multiple myeloma can be challenging on many levels. The person who has just been diagnosed may look to you for information to help them better understand the disease to ...

In a new study published in Cancer, researchers from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine’s Department of Pathology examine this disparity more closely, ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple myeloma treatment paradigm, the drug is still finding ways to consolidate its ...

Daratumumab and hyaluronidase-fihj is now FDA-approved for newly diagnosed multiple myeloma patients ineligible for ASCT, in combination with VRd. The phase 3 CEPHEUS trial showed significant ...

Palliative care that recognizes patient goals and values is essential, starting at diagnos ...

Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II) For over half a ...

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD. While teclistamab originally received ...

In a retrospective study, the non-relapse mortality rate at 1 year was 17% in those with CAR T-cell therapy-associated immune-related adverse events versus 2.7% in those without such events.